Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kala Bio Inc (NQ: KALA )

8.820 -0.140 (-1.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kala Bio Inc

< Previous 1 2 Next >
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From KALA BIO, Inc.
Via GlobeNewswire
KALA BIO to Participate in Upcoming Investor Conferences in August
From KALA BIO, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Announces Name Change to KALA BIO
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Here’s Why Sotera Health Company Stock Just Doubled in a Day
Sotera Health Company (NASDAQ: SHC) is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services. 
Via MarketBeat
Topics Emissions Initial Public Offering
Exposures Securities Market
Kala Pharmaceuticals Up 400% In The Past Month, What's Next ?
Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom. 
Via MarketBeat
Exposures Product Safety
Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END 
Via FinancialNewsMedia
Kala Pharmaceuticals (NASDAQ: KALA) Says FDA Accepted its IND Application for KPI-012 and Treatment of PCED
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and 
Via Spotlight Growth
Exposures Product Safety
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022 
From Kala Pharmaceuticals, Inc.
Via GlobeNewswire
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via Business Wire
Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx
From Kala Pharmaceuticals, Inc.
Via Business Wire
Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via Business Wire
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
From Kala Pharmaceuticals, Inc.
Via Business Wire
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
From Kala Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.